IterOnco Revenue

Biotechnology Research • Orsay, Île-de-France, France • 1-10 Employees

IterOnco revenue & valuation

Annual revenue	$256,665
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$821,328
Total funding	No funding

Key Contact at IterOnco

Manale Karam Doldur

Founder and Chief Executive Officer

Company overview

Headquarters	Orsay, Île-de-France, France
NAICS	541714
Keywords	Biotechnology, Clinical Research, Oncology, Pharmacology, Preclinical Research, Cancer Research, Research And Development, Cancer Therapy, Scientific Consulting, Efficacy Studies, Innovative Therapeutics, Cancer Treatment Innovation, Mechanisms Of Action, Nk Cell Immunotherapy, Natural Killer Cells, Paris-Saclay Biotechnology, Scientific Project Management
Founded	2024
Employees	1-10

About IterOnco

Founded in 2024 and strategically located in the Paris-Saclay University Park, France, IterOnco is an innovative French biotechnology startup dedicated to advancing cancer treatment and enhancing clinical outcomes through innovation and quality services. Behind our mission is a passionate team of scientists, researchers, and professionals who are deeply committed to making a difference. Every day, we work diligently with the belief that our efforts can bring real hope and improved quality of life to patients and their loved ones. As specialists in oncology, we are dedicated to driving breakthroughs in cancer research and treatment through three core activities: 1. Innovative Research & Development At IterOnco, we are embarking on a promising journey to develop next-generation cancer therapies, with a particular focus on Natural Killer (NK) cell immunotherapy. Our R&D efforts are dedicated to exploring and advancing novel therapeutic strategies that hold the potential to offer new hope in the fight against cancer. 2. Comprehensive Scientific & Regulatory Consulting Services We offer broad scientific and regulatory services to accelerate your projects and navigate the complexities of the biotechnology landscape. From project management and data analysis to crafting impactful scientific publications, preparing regulatory documents, and securing funding, our expertise is your advantage. 3. Advanced Preclinical In Vitro Services (Launching in 2025) In 2025, we will expand our offerings to include specialized preclinical in vitro services. Our capabilities will encompass detailed studies on pharmacology, toxicity, efficacy, and the identification of mechanisms of action, providing invaluable insights for your therapeutic development. Join Us on the Journey to Transform Cancer Treatment: IterOnco is not just a company; it's a commitment to innovation and excellence in oncology. Partner with us to push the boundaries of what’s possible in cancer treatment.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Employees by Department

IterOnco has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

IterOnco has never raised funding before.

Frequently asked questions

IterOnco is located in Orsay, Île-de-France, FR.

IterOnco generates an estimated annual revenue of $256,665. This revenue figure reflects the company's market position and business performance in its industry.

IterOnco has an estimated valuation of $821,328. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

IterOnco was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.

IterOnco has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at IterOnco

Manale Karam Doldur

Founder and Chief Executive Officer

4.8

40,000 users